CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
Sunitinib malate +1 moredrug
Likely dose
Sunitinib malate 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00730353
NCT00730353Phase 2Completed
CompareCT.gov

A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer

Hoosier Cancer Research Network·interventional·Posted Aug 8, 2008·Updated Mar 16, 2017

In Brief

A Phase 2 clinical trial evaluating Sunitinib malate and Paclitaxel for Esophageal Cancer. Completed, enrolled 28 participants across 15 sites.

Detailed Summary

Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings. We believe that the combination of paclitaxel and sunitinib malate offer great promise in the treatment of advanced esophageal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.9 years ago

Interventions

Sunitinib malatedrug

Sunitinib malate 37.5 mg orally, daily

Paclitaxeldrug

Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.